EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis

David Lauer, Cheryl Y Magnin, Luca R Kolly, Huijuan Wang, Matthias Brunner, Mamta Chabria, Grazia M Cereghetti, Hubert S Gabryś, Stephanie Tanadini-Lang, Anne-Christine Uldry, Manfred Heller, Stijn E Verleden und 7 weitere

JCI Insight · 2024

DOI: 10.1172/jci.insight.181757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2024. Verfasst von David Lauer und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, and. Hauptthemen laut MEDLINE: Indoles, Proteomics, Pulmonary Fibrosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lungenliga Schweiz, Innosuisse - Schweizerische Agentur für Innovationsförderung, Inselspital, Universitätsspital Bern.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antifibrotic therapy with nintedanib is the clinical mainstay in the treatment of progressive fibrosing interstitial lung disease (ILD). High-dimensional medical image analysis, known as radiomics, provides quantitative insights into organ-scale pathophysiology, generating digital disease fingerprints. Here, we performed an integrative analysis of radiomic and proteomic profiles (radioproteomics) to assess whether changes in radiomic signatures can stratify the degree of antifibrotic response to nintedanib in (experimental) fibrosing ILD. Unsupervised clustering of delta radiomic profiles revealed 2 distinct imaging phenotypes in mice treated with nintedanib, contrary to conventional densitometry readouts, which showed a more uniform response. Integrative analysis of delta radiomics and proteomics demonstrated that these phenotypes reflected different treatment response states, as further evidenced on transcriptional and cellular levels. Importantly, radioproteomics signatures paralleled disease- and drug-related biological pathway activity with high specificity, including extracellular matrix (ECM) remodeling, cell cycle activity, wound healing, and metabolic activity. Evaluation of the preclinical molecular response–defining features, particularly those linked to ECM remodeling, in a cohort of nintedanib-treated fibrosing patients with ILD, accurately stratified patients based on their extent of lung function decline. In conclusion, delta radiomics has great potential to serve as a noninvasive and readily accessible surrogate of molecular response phenotypes in fibrosing ILD. This could pave the way for personalized treatment strategies and improved patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesProteomicsPulmonary FibrosisAnimalsMiceHumansAntifibrotic AgentsDisease Models, AnimalFemaleMaleLungLung Diseases, InterstitialExtracellular Matrix

Stichwörter der Autor:innen

Diagnostic imagingFibrosisProteomicsPulmonologyTherapeutics

Substanzen

nintedanibIndolesAntifibrotic Agents

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, and.
  • Lung Precision Medicine (LPM), Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.
  • Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Graduate School for Cellular and Biomedical Sciences, University of Bern, Switzerland.
  • Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
  • Department of Diagnostic, Interventional, and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Förderung

  • Lungenliga Schweiz
  • Innosuisse - Schweizerische Agentur für Innovationsförderung
  • Inselspital, Universitätsspital Bern

Zitieren

APA

Lauer, D., Magnin, C. Y., Kolly, L. R., Wang, H., Brunner, M., Chabria, M., Cereghetti, G. M., Gabryś, H. S., Tanadini-Lang, S., Uldry, A. C., Heller, M., Verleden, S. E., Klein, K., Sarbu, A. C., Funke-Chambour, M., Ebner, L., Distler, O., Maurer, B., & Gote-Schniering, J. (2024). Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis. JCI Insight. https://doi.org/10.1172/jci.insight.181757

Vancouver

Lauer D, Magnin CY, Kolly LR, Wang H, Brunner M, Chabria M, et al. Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis. JCI Insight. 2024. doi:10.1172/jci.insight.181757

BibTeX
@article{Lauer2024,
  author = {Lauer, David and Magnin, Cheryl Y and Kolly, Luca R and Wang, Huijuan and Brunner, Matthias and Chabria, Mamta and Cereghetti, Grazia M and Gabryś, Hubert S and Tanadini-Lang, Stephanie and Uldry, Anne-Christine and Heller, Manfred and Verleden, Stijn E and Klein, Kerstin and Sarbu, Adela-Cristina and Funke-Chambour, Manuela and Ebner, Lukas and Distler, Oliver and Maurer, Britta and Gote-Schniering, Janine},
  title = {Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis},
  journal = {JCI Insight},
  year = {2024},
  doi = {10.1172/jci.insight.181757}
}
Kostenlos starten →